BiotechTube
Syntrix Pharmaceuticals

Syntrix Pharmaceuticals

Auburn, United States· Est.
syntrixbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.3M

Overview

Syntrix Pharmaceuticals is a private, clinical-stage biotech company leveraging a technology-agnostic, needs-driven research approach to develop novel therapeutics. Its pipeline features advanced clinical candidates in immuno-oncology (SX-682) and pain (desmetramadol), supported by a lean management team and a prestigious network of scientific advisors from top cancer centers. The company's strategy combines internal medicinal chemistry discovery with external collaboration and potential strategic acquisitions to build a robust portfolio targeting cancer and inflammatory diseases.

OncologyPainAutoimmunity

Technology Platform

Convergent Science & Strategy model: A technology-agnostic, needs-driven approach integrating medicinal chemistry, external research, IP strategy, and business development from project inception.

Funding History

2
Total raised:$4.3M
Grant$2.5M
Grant$1.8M

Opportunities

SX-682 addresses a key mechanism (myeloid suppression) in the large and growing immuno-oncology market, with potential for combination therapies.
Desmetramadol targets the vast pain management market with a need for safer, effective analgesics amidst the opioid crisis.
The company's agile strategy allows it to pursue high-value unmet needs across therapeutic areas.

Risk Factors

Clinical failure of lead candidates SX-682 or desmetramadol is the primary risk.
As a private, pre-revenue company, it faces ongoing financing risk to fund trials.
Intense competition in both oncology and pain markets requires clear differentiation for success.

Competitive Landscape

In immuno-oncology, Syntrix competes with numerous biopharma companies developing myeloid-targeting therapies and combination regimens. In pain, it faces competition from companies developing novel opioids, non-opioid analgesics, and neuromodulators. Its differentiation lies in its specific molecule profiles and convergent development strategy.

More companies in Small Molecule Drugs →More companies in United States →